Correction to Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet Oncology (2019) 20(3) (408–419), (S147020451830860X), (10.1016/S1470-2045(18)30860-X))
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Correction to Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet Oncology (2019) 20(3) (408–419), (S147020451830860X), (10.1016/S1470-2045(18)30860-X))

not, found
the lancet oncology 2019 Vol. 20 pp. e559
226
not2019correctionthe

Access

DOI:
10.1016/S1470-2045(19)30587-X

Citation

ID: 61306
Ref Key: not2019correctionthe
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
61306
Unique Identifier:
10.1016/S1470-2045(19)30587-X
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
4/5
Blockchain Upload Locked

Complete all 5 checklist items to tokenize your article

Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store